Results 211 to 220 of about 3,106,146 (396)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma [PDF]

, 2014
Noah Merin, Kevin R. Kelly
openalex   +1 more source

Dual-targeting proteasome inhibitor ONX-0914 demonstrates potent antiplasmodial activity for malaria treatment. [PDF]

Int J Parasitol Drugs Drug Resist
Van Truong N, Nguyen TK, Thau NS, Chu TH, Sanaullah B, Venkataramaiah C, Han JH, Na SH, Park WS, Chun WJ, No JH, Han ET.   +11 more
europepmc   +1 more source

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma. [PDF]

Blood Adv, 2023
Heynen GJJE, Baumgartner F, Heider M, Patra U, Holz M, Braune J, Kaiser M, Schäffer I, Bamopoulos SA, Ramberger E, Murgai A, Ng YLD, Demel UM, Laue D, Liebig S, Krüger J, Janz M, Nogai A, Schick M, Mertins P, Müller S, Bassermann F, Krönke J, Keller U, Wirth M.   +24 more
europepmc   +1 more source

OCIAD2 Stabilizes Integrin β1 Signaling Through SNX17‐Mediated Endosomal Recycling to Lipid Rafts and Modulates Cisplatin Response in HNSCC

Advanced Science, EarlyView.
This study identifies OCIAD2 as a critical regulator of cisplatin resistance in HNSCC. Mechanistically, OCIAD2 stabilizes integrin β1 through a direct physical interaction and facilitates its SNX17‐dependent endosomal recycling to lipid raft microdomains. Targeting OCIAD2 disrupts integrin β1 trafficking and significantly enhances cisplatin sensitivity,
Li Cui, Shanshan Si, Min Ye, Pei Lin, Meiyan Zou, Yunfan Lin, Xu Chen, Bing Guo, Wenjuan Sun, Xinyuan Zhao   +9 more
wiley   +1 more source

Biosynthesis of lactacystin as a proteasome inhibitor. [PDF]

Commun Chem
Tsunoda T, Furumura S, Yamazaki H, Maruyama C, Hamano Y, Ogasawara Y, Dairi T.   +6 more
europepmc   +1 more source

Halorotetin B, A Novel Terpenoid Compound Derived from Marine Ascidian, Suppresses Tumor Growth by Targeting the Cell Cycle Regulator UBE2C

Advanced Science, EarlyView.
Halorotetin B, a novel small‐molecule terpenoid identified from an edible marine ascidian, exhibits strong anti‐tumor activity both in vitro and in vivo through direct targeting UBE2C to induce tumor cell cycle arrest and then lead tumor cell senescence. As a newly discovered UBE2C inhibitor, Halorotetin B can serve as a novel potential cell senescence
Shanhao Han, Jianhui Li, Yuting Zhu, Penghui Liu, Yaoyao Zheng, Muchun He, Bo Dong   +6 more
wiley   +1 more source

Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells

, 2010
Mohamed Salah I. Abaza
openalex   +2 more sources

Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in Sweden. [PDF]

Clin Hematol Int
Luong V, Kashif M, Uttervall K, Bohlin A, Öster Fernström A, Qu Y, Lee S, Mendes J, Van Hoorenbeeck S, Hellqvist Franck E, He J, Alici E, Lund J.   +12 more
europepmc   +1 more source

Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer. [PDF]

Molecules, 2023
Zhang J, Sun S, Liu J, Zhang L, Guo D, Zhang N, Zhao J, Kong D, Xu T, Wang X, Xu W, Li X, Jiang Y.   +12 more
europepmc   +1 more source

DNA Nanoflower LYTACs Enable Efficient VEGF Degradation and Verteporfin Loading for Combined Therapy of Wet Age‐Related Macular Degeneration

Advanced Science, EarlyView.
An integrated approach that combines a DNA nanoflower VEGF degrader with photodynamic therapy is developed for the treatment of wet age‐related macular degeneration, which reduces the risk of VEGF reactivation‐induced CNV recurrence and minimizes the systemic side effects associated with photodynamic therapy.
Mengxuan Li, Yan Yue, Sijin Wu, Xinyu He, Jiayi Song, Shuwen Ma, Haokun Zhang, Chenyu Xu, Song Chen, Yanming Huang, Songbo Xie, Hua Yan   +11 more
wiley   +1 more source